This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

AbbVie attempting to rewrite US antitrust case over Humira, plaintiffs argue

( May 29, 2025, 22:31 GMT | Official Statement) -- MLex Summary: AbbVie's motion to dismiss US antitrust claims attempts to rewrite the complaint accusing it of entering into illegal agreements with pharmacy benefit managers to ensure that Humira would be positioned favorably on formularies, plaintiffs argued in a brief opposing the motion to dismiss. “AbbVie’s re-write ignores the Complaint’s well pleaded allegations: AbbVie did not provide discounts, it imposed penalties—it jacked up the net prices of Humira, Skyrizi, and Rinvoq to supracompetitive levels and then withheld rebates from health plans that rejected the restraints; the scheme increased patient cost-sharing and imposed billions in overcharges on health plans; and plaintiff alleges that AbbVie’s prices were too high, not too low,” they said.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections